trending Market Intelligence /marketintelligence/en/news-insights/trending/exwl46cphyzmbdyzhqc_yg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

RavenQuest BioMed to buy 51% of Elephant Extracts

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


RavenQuest BioMed to buy 51% of Elephant Extracts

RavenQuest BioMed Inc. intends to acquire 51% of Elephant Extracts' outstanding share capital.

The Vancouver, British Columbia-based cannabis producer entered into a letter of intent with Elephant Extracts, whose official business name is 1090252 B.C. Ltd., to acquire a controlling interest in the company.

Elephant Extracts may redeem the interest after it receives a license to produce under Canada's Access to Cannabis for Medical Purposes Regulations. RavenQuest will be granted an ongoing royalty of 15% of the gross revenue from production at a 10,000 square foot facility developed by Elephant Extracts.

Completion of the deal is subject to completion of due diligence, a definitive agreement and regulatory approvals.